IMMUNOVANT INC. DL-,0001

Immunovant shares rose to a 52-week high of $41.37 and are currently trading at $41.44. Market capitalization is around $8.48 billion, and total return over the past year is about 169%. An analysis by InvestingPro rates the stock as overvalued relative to its fair value. » Más en de.investing.com

Immunovant’s stock reached a 52-week high of $39.28, bringing market capitalization to $8.01 billion after a one-year gain of 130.79%. Analysts raised price targets—H.C. Wainwright $40, BofA $43 and Stifel $49—citing convincing Phase 2 response rates for IMVT-1402 in rheumatoid arthritis (ACR20/50/70). Roivant reported a Q4 EPS miss but emphasized strategic growth and a strong cash position. The positive trial data are currently driving investor sentiment and future share-price expectations. » Más en de.investing.com

H.C. Wainwright lifted its price target for Immunovant to $40 from $35 and kept a Buy rating after Phase 2 rheumatoid arthritis data showed high response rates and efficacy despite prior exposure to advanced therapies. The firm raised the probability of success for IMVT-1402 in RA to 55% and increased its EV/sales multiple to 10x. BofA also raised its target to $43 and boosted peak sales forecasts for IMVT-1402 to $6.8 billion, citing stronger contributions from Graves’ disease and severe RA. IMVT-1402 is a fully human monoclonal antibody targeting the neonatal Fc receptor (FcRn). » Más en finance.yahoo.com